AstraZeneca and Merck & Co’s latest attempt to revive an old pipeline drug cediranib has failed as it did not improve survival compared with chemotherapy in advanced ovarian cancer, in
NICE has been busy with announcements today, rejecting Astellas’ Xospata for a certain type of acute myeloid leukaemia (AML) and querying evidence for MSD's Keytruda in head and neck cancer
